Okay, here’s a revised and fact-checked version of the provided text, incorporating current information as of today, January 23, 2024. I’ve focused on verifying claims, correcting inaccuracies, and adding context where needed. I’ve also noted changes made at the end.
—
## The Emerging Role of Mucosal Immunity in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease primarily affecting the joints, but increasingly, research suggests its origins may lie outside of them. The mucosal origins hypothesis posits that the early autoimmunity of RA is triggered by inflammation at mucosal surfaces – such as the gums, lungs, and gut. According to this theory, joint involvement occurs later in the disease process. This is a critically important shift from the traditional view of RA as primarily a joint-specific disease.
More research is needed, but the mucosal origins hypothesis offers a compelling description for several established risk factors. Periodontal disease (gum disease) has a strong association with RA, possibly due to the presence of *Porphyromonas gingivalis*, a bacterium that can citrullinate proteins – a key process in RA pathogenesis. Emphysema and other forms of lung disease are also linked to increased RA risk, possibly due to lung inflammation and immune dysregulation. Exposure to environmental factors like tobacco smoke and, increasingly, air pollution (including that from forest fires) are also recognized risk factors, contributing to mucosal inflammation. Furthermore, specific gut bacteria and alterations in the gut microbiome have been associated with RA development and progression. Future therapeutic strategies targeting mucosal inflammation could represent a novel approach to RA prevention and treatment.
MoMo Productions/DigitalVision via Getty Images
Predicting Disease Onset and the Challenge of Prevention Trials
While biomarkers like anti-cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) are valuable in predicting future RA,a significant challenge remains: a significant proportion of individuals who test positive for these autoantibodies never develop clinical RA.
Studies indicate that approximately 20% to 30% of individuals positive for anti-CCP antibodies develop RA within two to five years. Though,the presence of multiple risk factors – including smoking,genetic predisposition,and shared epitope alleles – can elevate the risk to Keep reading